In contrast, enteral CDCA treatment was not effective in preventing cholestasis or upregulation of bile acid transporters, even though it suppressed the key bile acid synthesis gene CYP7A1. Our findings in pigs and other recent work in mice suggest that NR1H4-mediated activation of key hepatobiliary ATP-binding cassette transporters is sufficient to maintain hepatic bile flow and prevent liver injury. The gene discussed is ABCA4; the disease is cholestasis.